Pain: GPCR and Nerve Growth Factor-Based Therapies Offer Strong Potential in Difficult-to-Treat Subtypes

2019-04-17
Price :
Published : Apr-2019
No. of Pages : 75

Pain: GPCR and Nerve Growth Factor-Based Therapies Offer Strong Potential in Difficult-to-Treat Subtypes

Summary

The pain therapeutics market has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established active pharmaceutical ingredients and mechanisms of action. The moderate-to-severe pain space continues to be dominated by opioids, which are increasingly being reformulated to offer abuse resistance, whereas mild pain is effectively treated with non-steroidal anti-inflammatory drugs (NSAIDs). However, significant unmet needs remain, as chronic pain subtypes-particularly neuropathic pain-do not respond well to existing therapies. This report assesses first-in-class innovation across the pain pipeline.

Scope

– There are 909 pipeline programs in active development for pain. What proportion of these products are first-in-class? How does first-in-class innovation vary by development stage and molecular target class?
– The market for pain treatment is heavily saturated. Which drug classes are used to treat pain? How do the drug classes in the market compare with those in the pipelines?
– Which molecular target classes are prominently represented in the first-in-class pain pipelines? Which first-in-class targets have been identified as most promising for the treatment of pain? Which first-in-class products have prior deal involvement?

Reasons to buy

– Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems and epidemiology for major pain subtypes.
– Visualize the composition of the pain market in terms of dominant molecule types and molecular targets. This knowledge allows a competitive understanding of gaps in the current market.
– Analyze and compare the pain pipeline and stratify by stage of development, molecule type, and molecular target.
– Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
– Recognize commercial opportunities by identifying first-in-class pipeline products for pain that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for first-in-class pain products.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Hepatitis B: Competitive Landscape to 2027

Hepatitis B: Competitive Landscape to 2027 Summary Hepatitis B is a viral infection of the liver that can become chronic in young children, especially newborns to mothers with HBV infections, and people with compromised immune systems. Chronic hepatitis B is defined as measurable Hepatitis surface antigen (HBsAg) levels for more than six months after an acute infection. Despite the existence of prophylactic vaccines, hepatitis B remains a global public health threat, with approximately 257 million people worldwide living with chronic HBV infections. Chronic hepatitis B cannot be cured and patients have elevated risks of developing liver cirrhosis and hepatocellular carcinoma (HCC). This report provides an assessment of the pipeline, clinical, and commercial landscape of Hepatitis B. Ov......
$3495

Pediatric Vaccines: Epidemiology Forecast to 2028

Pediatric Vaccines: Epidemiology Forecast to 2028 Summary The administration of a vaccine, referred to as vaccination, elicits an immune response that prevents an individual from developing a specific disease when exposed to the corresponding infectious agent in the future. A successful vaccination results in immunization, where the individual is deemed immune to the disease. Routine immunization programs aim to protect children at an early age, when they are the most vulnerable to disease. Prior to the discovery of vaccines, several infectious diseases claimed the lives of millions of children each year. GlobalData epidemiologists utilized comprehensive, country-specific vaccination rate data from nationally representative public health surveillance systems and databases to arrive at ......
$3995

Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects

Parkinson's Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects Summary Parkinson's disease (PD), a progressive neurological disorder that affects movement control, is associated with considerable quality of life impairments and burden of care, particularly in the advanced disease stages. Cognitive and behavioral complications of PD are common. PD-associated dementia and PD-associated psychosis are both highly prevalent and associated with a large disease burden. There is a pressing unmet need within PD, PD-associated dementia, and PD-associated psychosis for more effective disease-modifying pharmacotherapies. Although current therapies can provide patients with symptomatic relie......
$6995

Obesity: Gut Hormone Receptors Retain Commercial Prominence

Obesity: Gut Hormone Receptors Retain Commercial Prominence Summary Obesity is a chronic and potentially fatal disease. The most prevalent metabolic disorder affecting people today, obesity requires multidisciplinary continuing treatment. Despite the market's clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, which is in line with its multifactorial etiology. The primary concern within the market is the need for medications that adequately address the unmet clinical needs in the overweight and obese population, namely efficacious and safe therapies. This report assesses first-in-class innovation across the obesity pipeline. Scope - The obesity pipeline is robust and contains a high leve......
$6995

Chronic Inflammation Global Clinical Trials Review, H1, 2019

Chronic Inflammation Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Chronic Inflammation Global Clinical Trials Review, H1, 2019" provides an overview of Chronic Inflammation clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Inflammation. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinic......
$2500

Contrast Induced Nephropathy Global Clinical Trials Review, H1, 2019

Contrast Induced Nephropathy Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Contrast Induced Nephropathy Global Clinical Trials Review, H1, 2019" provides an overview of Contrast Induced Nephropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Contrast Induced Nephropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary......
$2500

Closed-Angle Glaucoma Global Clinical Trials Review, H1, 2019

Closed-Angle Glaucoma Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Closed-Angle Glaucoma Global Clinical Trials Review, H1, 2019" provides an overview of Closed-Angle Glaucoma clinical trials scenario. This report provides top line data relating to the clinical trials on Closed-Angle Glaucoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Cl......
$2500

Cyst Global Clinical Trials Review, H1, 2019

Cyst Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Cyst Global Clinical Trials Review, H1, 2019" provides an overview of Cyst clinical trials scenario. This report provides top line data relating to the clinical trials on Cyst. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ differ......
$2500

Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H1, 2019

Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H1, 2019" provides an overview of Community-Acquired Bacterial Pneumonia clinical trials scenario. This report provides top line data relating to the clinical trials on Community-Acquired Bacterial Pneumonia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are ......
$2500

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2019

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2019" provides an overview of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (ba......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy